In a brief statement, the embattled drugmaker confirmed that negotiations its lenders are ongoing following the expiration of its standstill agreement on February 7, 2020.
According to Akorn, it will continues to evaluate strategic alternatives to address its litigation-related liabilities.
News of Fresenius taking over Akorn began in 2017, but the takeover was cancelled after data integrity concerns cropped up.
Read the full Akorn Pharmaceuticals statement